Uncategorized

Mar. 25, 2019 Bioasis Technologies Inc. Announces Warrant Extension

GUILFORD, Conn. — (BUSINESS WIRE) — BIOASIS TECHNOLOGIES INC. (“Bioasis” or the “Company”) (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »